The company is a clinical-stage biopharmaceutical firm developing targeted small-molecule therapies for cancer, specifically RAS(ON) inhibitors designed to treat tumors driven by oncogenic RAS pathway mutations such as KRAS G12C and KRAS G12D. It has advanced three lead candidate drugs through clinical development, often evaluated in combination with existing approved therapies or other investigational agents, supported by companion diagnostic strategies to identify appropriate patient populations. The company has no approved products or product revenues and operates by outsourcing manufacturing to third parties and clinical development to contract research organizations, with its future business dependent on obtaining regulatory approvals and establishing commercialization partnerships or capabilities.